| __timestamp | Exelixis, Inc. | Viatris Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 50829000 | 1499100000 |
| Thursday, January 1, 2015 | 57305000 | 1923500000 |
| Friday, January 1, 2016 | 116145000 | 2351400000 |
| Sunday, January 1, 2017 | 159362000 | 2564000000 |
| Monday, January 1, 2018 | 206366000 | 2397300000 |
| Tuesday, January 1, 2019 | 228244000 | 2503400000 |
| Wednesday, January 1, 2020 | 293355000 | 3344600000 |
| Friday, January 1, 2021 | 401715000 | 4529200000 |
| Saturday, January 1, 2022 | 459856000 | 4179100000 |
| Sunday, January 1, 2023 | 542705000 | 4650100000 |
Unleashing the power of data
In the ever-evolving pharmaceutical industry, understanding the financial dynamics of key players is crucial. Over the past decade, Viatris Inc. and Exelixis, Inc. have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Viatris Inc. consistently reported higher SG&A expenses, peaking at approximately $4.65 billion in 2023, a 210% increase from 2014. In contrast, Exelixis, Inc. demonstrated a more modest growth, with expenses rising from $50 million in 2014 to $543 million in 2023, marking a tenfold increase. This disparity highlights Viatris's expansive operational scale compared to Exelixis's focused growth strategy. As the industry faces increasing regulatory and competitive pressures, these financial trends offer insights into each company's strategic priorities and market positioning.
Breaking Down SG&A Expenses: Zoetis Inc. vs Viatris Inc.
Alnylam Pharmaceuticals, Inc. and Viatris Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Viatris Inc. and Ascendis Pharma A/S
SG&A Efficiency Analysis: Comparing Viatris Inc. and BioMarin Pharmaceutical Inc.
Selling, General, and Administrative Costs: Viatris Inc. vs Ultragenyx Pharmaceutical Inc.
Operational Costs Compared: SG&A Analysis of Viatris Inc. and Corcept Therapeutics Incorporated
Who Optimizes SG&A Costs Better? Viatris Inc. or CRISPR Therapeutics AG
Cost Management Insights: SG&A Expenses for Viatris Inc. and BioCryst Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Exelixis, Inc. and Opthea Limited
Exelixis, Inc. and ADMA Biologics, Inc.: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Exelixis, Inc. or Iovance Biotherapeutics, Inc.
Selling, General, and Administrative Costs: Exelixis, Inc. vs BioCryst Pharmaceuticals, Inc.